Sagimet Biosciences Inc.

NASDAQ:SGMT

Biotechnology

Healthcare
$10.11 +1.38%

+$0.09 today

Market cap
$711.15M
Beta
3.44
P/E (TTM)
-5.0
EPS (TTM)
-$1.34
52W Low $4.50High $11.41

Volume 0.93M

Average 1.49M

SGMT Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Sagimet Biosciences Inc.NASDAQ: SGMT

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares grows in line with its trailing trend

Q1 FY2026 weighted avg shares of 32.56M shares rose 1.1% year over year, in line with the +0.9% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 0.7% from the prior quarter. Over 3 fiscal years it compounded at +13.4% a year.

Context

  • Weighted avg shares increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +1.1% holds above the trailing-twelve-month pace of +0.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
32.56M+0.7% QoQ
Last fiscal yearDec 2025
32.35M+3.2% YoY
LTMMar 2026
32.39M+0.9% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1.1%——
1 year+3.2%——
3-year CAGR+13.4%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
32.35M USD
Year-over-year change
+3.2%
4-year CAGR
+9.9%

Weighted Avg Shares vs competitors

How SGMT compares with its peers on the latest reported figures

  • SGMT's LTM Mar 2026 weighted avg shares of 32.39M shares is the 9th highest of the 11 companies compared; the peer median is 53.5M shares.
  • Its year-over-year change of +0.9% is the 10th highest of 11, against a peer median of +18.9%.
  • Over three fiscal years its annual growth of +13.4% compares with a peer median of +15.3%.
SGMT Competitors Peer median
Weighted Avg Shares for SGMT and competitors
Company Period LTM YoY 3-year CAGR
HUMAHumacyte, Inc.LTM Mar 2026167.44M +37.1%+15.3%
ZURAZura Bio LimitedLTM Mar 202698.81M +34.9%+76.1%
AVIRAtea Pharmaceuticals, Inc.LTM Mar 202680.03M -5.4%-0.7%
FHTXFoghorn Therapeutics Inc.LTM Mar 202664.63M +7.9%+14.8%
VYGRVoyager Therapeutics, Inc.LTM Mar 202658.91M +1.6%+15.2%
ACHVAchieve Life Sciences, Inc.LTM Mar 202648.09M +39.5%+60.3%
TRDAEntrada Therapeutics, Inc.LTM Mar 202641.5M +5.9%+9.8%
IMRXImmuneering CorporationLTM Mar 202640.92M +29.8%+18.6%
SGMTSagimet Biosciences Inc.LTM Mar 202632.39M +0.9%+13.4%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 202627.53M +1.8%+1.2%
ASMBAssembly Biosciences, Inc.LTM Mar 202610.86M +66.5%+40.6%
Peer median (excluding SGMT) 53.5M+18.9%+15.3%

Competitors are the stored peer set for SGMT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue002M00
Cost of Revenue00000
Gross Profit002M00
Gross Margin——100.0%——
Research & Development19.34M24.92M19.78M38.44M39.05M
Selling, General & Admin4.38M6.14M12.96M16.01M17.84M
Operating Expenses23.72M31.06M32.74M54.45M56.89M
Depreciation & Amortization0130K000
EBITDA(24.44M)(30.37M)(27.88M)(45.57M)(51.04M)
EBITDA Margin——-1393.8%——
Operating Income(23.72M)(31.06M)(30.74M)(54.45M)(56.89M)
Operating Margin——-1537.0%——
Interest Income26K553K2.86M8.89M5.85M
Interest Expense00000
Other Income / Expenses(723K)556K2.86M8.89M5.85M
Income Before Tax(24.44M)(30.5M)(27.88M)(45.57M)(51.04M)
Pre-Tax Margin——-1393.8%——
Income Tax Expense00000
Net Income(24.44M)(30.5M)(27.88M)(45.57M)(51.04M)
Net Margin——-1393.8%——
EPS (Basic)(1.10)(1.38)(1.53)(1.45)(1.58)
EPS (Diluted)(1.10)(1.38)(1.53)(1.45)(1.58)
Weighted Avg Shares22.17M22.17M18.19M31.35M32.35M
Weighted Avg Shares (Diluted)22.17M22.17M18.19M31.35M32.35M

Sagimet Biosciences Inc.

NASDAQ:SGMT

Intrinsic Alpha fair value

Locked

Current Price

$10.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.